Publications by authors named "Brendan Tobin"

Article Synopsis
  • Current treatments for craniofacial bone abnormalities, which include surgeries and bone grafts, are costly and have significant limitations, with some therapies posing serious health risks.
  • Bone morphogenetic protein 2 (BMP2) has issues like overgrowth and inflammation, while stem cell therapies are promising but not FDA approved and resource-heavy.
  • Research suggests that JAGGED1 can effectively promote bone regeneration in pediatric patients by inducing specific signaling pathways in osteoblasts, presenting a potential innovative treatment option for craniofacial bone loss.
View Article and Find Full Text PDF

Microglia are resident immune cells of the brain and regulate its inflammatory state. In neurodegenerative diseases, microglia transition from a homeostatic state to a state referred to as disease-associated microglia (DAM). DAM express higher levels of proinflammatory signaling molecules, like STAT1 and TLR2, and show transitions in mitochondrial activity toward a more glycolytic response.

View Article and Find Full Text PDF

Dysfunction in fast-spiking parvalbumin interneurons (PV-INs) may represent an early pathophysiological perturbation in Alzheimer's Disease (AD). Defining early proteomic alterations in PV-INs can provide key biological and translationally-relevant insights. We used cell-type-specific in-vivo biotinylation of proteins (CIBOP) coupled with mass spectrometry to obtain native-state PV-IN proteomes.

View Article and Find Full Text PDF

Treatments for congenital and acquired craniofacial (CF) bone abnormalities are limited and expensive. Current reconstructive methods include surgical correction of injuries, short-term bone stabilization, and long-term use of bone grafting solutions, including implantation of (i) allografts which are prone to implant failure or infection, (ii) autografts which are limited in supply. Current bone regenerative approaches have consistently relied on BMP2 application with or without addition of stem cells.

View Article and Find Full Text PDF

One of the earliest pathophysiological perturbations in Alzheimer's Disease (AD) may arise from dysfunction of fast-spiking parvalbumin (PV) interneurons (PV-INs). Defining early protein-level (proteomic) alterations in PV-INs can provide key biological and translationally relevant insights. Here, we use cell-type-specific in vivo biotinylation of proteins (CIBOP) coupled with mass spectrometry to obtain native-state proteomes of PV interneurons.

View Article and Find Full Text PDF